Skip to main content

Table 2 CTC counts and morphologic characteristics in relation to breast cancer subtypea

From: Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort

Variables

All patients

N = 52

Hormone receptor positive

(ER+, PgR±, HER2-)

N = 39

HER2 positive

(HER2+, ER±, PgR±)

N = 7

Triple-negative

(ER-, PgR-, HER2-)

N = 4

P-value

CTC number

     

 CTC count at BL median (range)

45 (5–668)

44 (5–668)

111 (12–311)

88 (39–253)

0.32

 CTC count at 1–3 mo median (range)

4 (0–263)

4 (0–263)

0 (0–9)

87 (75–144)

0.007

 CTC count at 6 mo median (range)

1 (0–765)

1 (0–765)

0 (0–183)

2 (2–2)

0.18

  ≥ 5 CTC at 1–3 mo

    

0.29

 Yes

19

15

1

3

 

 No

29

22

5

1

 

 Missing

4

2

1

0

 

  ≥ 5 CTC at 6 mo

    

0.72

 Yes

14

12

1

1

 

 No

27

19

5

1

 

 Missing

11

8

1

2

 

Apoptosis

     

 Apoptotic CTC at BL

    

0.20

 Yes

40

29

6

4

 

 Median number (range)

5 (1–54)

3 (1–52)

6.5 (1–54)

6.5 (5–40)

 

 Median fraction (range)

0.08 (0.01–0.33)

0.09 (0.01–0.33)

0.07 (0.04–0.17)

0.12 (0.05–0.18)

 

 No

12

10

1

0

 

 Missing

0

0

0

0

 

 Apoptotic CTC 1–3 mo

    

0.17

 Yes

17

13

1

3

 

 Median number (range)

3 (1–18)

3 (1–18)

2

6 (3–9)

 

 Median fraction (range)

0.13 (0.01–1.0)

0.13 (0.01–1.0)

0.22

0.04 (0.04–0.10)

 

 No

31

24

5

0

 

 Missing

4

2

1

1

 

 Apoptotic CTCs 6 mo

    

0.49

 Yes

15

12

1

2

 

 Median number (range)

2 (1–109)

2 (1–109)

2

3 (1–5)

 

 Median fraction (range)

0.09 (0.01–1.0)

0.11 (0.02–1.0)

0.01

0.29 (0.09–0.50)

 

 No

26

19

5

0

 

 Missing

11

8

1

2

 

Clusters

     

 Clusters at BL

    

0.010

 Yes

9

4

3

2

 

 Median number (range)

2 (1–18)

3 (1–18)

4 (1–4)

1.5 (1–2)

 

 Median fraction (range)

0.02 (0.003–0.03)

0.02 (0.003–0.03)

0.01 (0.005–0.02)

0.02 (0.02–0.03)

 

 No

43

35

4

2

 

 Missing

0

0

0

0

 

 Clusters at 1–3 mo

    

0.026

 Yes

5

3

0

2

 

 Median number (range)

1 (1–4)

1 (1–4)

 

1 (1)

 

 Median fraction (range)

0.009 (0.006–0.02)

0.009 (0.006–0.02)

 

0.01 (0.007–0.01)

 

 No

43

34

6

1

 

 Missing

4

2

1

1

 

 Clusters at 6 mo

    

0.98

 Yes

4

3

1

0

 

 Median number (range)

6 (1–16)

10 (2–16)

1

  

 Median fraction (range)

0.003 (0.001–0.006)

0.001 (0.001–0.005)

0.006

  

 No

37

28

5

2

 

 Missing

11

8

1

2

 

WBC-CTC

     

 WBC-CTC at BL

    

0.45

 Yes

35

26

6

3

 

 Median number (range)

4 (1–38)

3 (1–38)

6.5 (1–13)

4 (2–22)

 

 Median fraction (range)

0.05 (0.004–0.6)

0.05 (0.004–0.6)

0.07 (0.02–0.2)

0.04 (0.03–0.09)

 

 No

17

13

1

1

 

 Missing

0

0

0

0

 

 WBC-CTC at 1–3 mo

    

0.61

 Yes

12

10

0

2

 

 Median number (range)

3.5 (1–101)

3.5 (1–28)

 

51.5 (2–101)

 

 Median fraction (range)

0.1 (0.02–1)

0.1 (0.04–1)

 

0.4 (0.02–0.7)

 

 No

36

27

6

1

 

 Missing

4

2

1

1

 

 WBC-CTC at 6 mo

    

0.49

 Yes

8

6

1

1

 

 Median number (range)

6 (1–62)

5.5 (1–62)

9

3

 

 Median fraction (range)

0.05 (0.009–0.09)

0.04 (0.009–0.09)

0.05

0.05

 

 No

33

25

5

1

 

 Missing

11

8

1

2

 
  1. WBC-CTC white blood cells associated with CTC, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, BL base-line, NHG Nottingham histological grade, MBC metastatic breast cancer, mo months
  2. a Breast cancer subtype was derived from the primary tumor (n = 40) and, if no primary tumor tissue was available, from the metastasis (n = 10). Two patients had insufficient tissue for subtype assessment